Skip to content

Utility of Transdermal Optical Imaging (TOI) as a Non-invasive Measure of Hydration Status: Phase 3a for Model Development

Utility of Transdermal Optical Imaging TOI) as a Non-invasive Measure of Hydration Status: Phase 3a for Model Development

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06044610
Enrollment
32
Registered
2023-09-21
Start date
2023-05-08
Completion date
2023-11-15
Last updated
2024-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dehydration

Keywords

hydration, dehydration, euhydration, hypohydration, exercise, Transdermal Optical Imaging, TOI

Brief summary

The primary objective of this study is to analyze smart phone-based Transdermal Optical Imaging (TOI) features to develop a model that can discern hypohydration from euhydration status including 1) a small feasibility study for 24-hour data collection in the general population using passive dehydration or ad libitum fluid intake (GENPOP), 2) an exercise study in moderately active participants in both dehydrated and euhydrated states (EXERCISE). TOI data will be collected alongside standard reference measures of hydration status. This is an exploratory pilot proof of concept study with each subject serving as their own control.

Interventions

OTHERGENPOP Passive dehydration (75% reduction in fluid intake

Over 24-hours

OTHERGENPOP Ad lib fluid intake

Over 24 hours

OTHEREXERCISE without fluid replacement

90-min standard cycling exercise trial in heat chamber

OTHEREXERCISE with fluid replacement

90-min standard cycling exercise trial in heat chamber

Sponsors

PepsiCo Global R&D
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Subject is male or female * If female, subject is not pregnant * For GENPOP study subject is 18-65 years of age, inclusive * For EXERCISE study subject is 18-50 years of age, inclusive * Subject is moderately-trained (engages in moderate-intensity, intermittent, or steady-state exercise at least 3 days per week for at least 1 hour at a time (EXERCISE session participants only) * Subject does not smoke (or has quit for at least 6 months) * Subject is not taking medication that may interfere with the study * Subject has no health conditions that would prevent completion of the trial as indicated on the general health questionnaire (GHQ) * Subject is willing to avoid alcohol consumption 24 hours prior to visit(s) * Subject is willing to fast overnight (\ 8-12 hours) * For GENPOP, subject is willing to refrain from vigorous exercise for 48 hours * For EXERCISE, subject is willing to refrain from vigorous exercise for 24 hours prior to study visits * Subject is willing to eat the exact same food the day prior to each visit to the laboratory * Subject is willing to avoid wearing makeup to the study session * Subject is willing to shave facial hair if predetermined during the informed consent session it will interfere with TOI measurement * Able to speak, write, and read English * Provision of written consent to participate

Exclusion criteria

* Subject has participated in a clinical trial within the past 30 days * Subject has participated in any PepsiCo trial within past 6 months * Subject has a condition or is taking medication that the investigator believes would interfere with his/her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the person at undue risk * Subject is allergic to alcohol or facial cleansing wipes * Subject has a history of anaphylaxis or severe allergic reactions * Subjects has a health condition or is taking medication that can be worsened by fluid restriction * Subject has asthma or other condition which breathing can become labored during exercise (EXERCISE session participants only) * Male subjects with a VO2max \< 42 ml/kg/min and females with a VO2max \< 38 ml/kg/min (EXERCISE session participants only) * Subject is employed by, or has a parent, guardian, or other immediate family member employed by a company that manufactures any products that compete with any Gatorade product. If subject is unsure if a company would be considered a competitor to Gatorade, they will be asked to please let the study investigator know the name of the other company and the nature of their relationship to that company before they sign the informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Transdermal optical imaging (TOI) signalsGENPOP: Before breakfast (~ 8 a.m.), before lunch ~11:30 a.m.), ~3:30 p,m., ~8.a.m. the following day. For EXERCISE, pre and post exercise session allowing for 30 minute cool down period.Blood flow patterns of the face obtained from the video camera on a smart phone
Standard measurements of hydration statusGENPOP: Before breakfast (~ 8 a.m.), before lunch ~11:30 a.m.), ~3:30 p,m., ~8.a.m. the following day. For EXERCISE, pre and post exercise sessions allowing for 30 minute cool down period.Body mass change, urine specific gravity, urine color (1-8 scale), and visual analogue scale to indicate thirst (1=not thirsty at all to 7 very, very thirsty)

Secondary

MeasureTime frameDescription
Mood scaleGENPOP: Before breakfast (~ 8 a.m.), before lunch ~11:30 a.m.), ~3:30 p,m., ~8.a.m. the following day9-point categorical scale from 1 (calm) to 9 (irritated)
Dietary and fluid intake24 hours prior to each visit through end of each study period.Log entries of food and drink
EXERCISE only: Rate of perceived exertion (RPE)Two 90 minute standard cycling exercise trials separated by approximately 3 to 7 daysBorg scale (6-20 scale) from no exertion at all to maximal exertion
EXERCISE only: Heart rateTwo 90 minute standard cycling exercise trials separated by approximately 3 to 7 days(beats/min)
EXERCISE only: Work rateTwo 90 minute standard cycling exercise trials separated by approximately 3 to 7 days(watts, rpm)
EXERCISE only: Fluid intake (euhydrated state)Two 90 minute standard cycling exercise trials separated by approximately 3 to 7 days(fluid volume in milliliters)
EXERCISE only: Sweating rateTwo 90 minute standard cycling exercise trials separated by approximately 3 to 7 daysRate of sweat over the course of the testing session.
DemographicsAt screeningAge, sex, ethnicity, race
EXERCISE only: Physical and mental energyTwo 90 minute standard cycling exercise trials separated by approximately 3 to 7 daysRated from 1=Energetic to 6= Worn out and from 1=Never to 5=Always.
EXERCISE only: Grittiness scoreTwo 90 minute standard cycling exercise trials separated by approximately 3 to 7 days8 item grit scale (examples: ideas, setbacks, goals)
EXERCISE only: Visual analogue scale for mental energy and fatigueTwo 90 minute standard cycling exercise trials separated by approximately 3 to 7 daysMarked on a horizontal line anchored by 0-100 mm with 0 (no energy and fatigue) to 100 mm (strongest feeling of energy and strongest feeling of fatigue ever felt)
EXERCISE only: Sweat biomarkersTwo 90 minute standard cycling exercise trials separated by approximately 3 to 7 days(electrolyte and metabolites)
EXERCISE only: Saliva biomarkersTwo 90 minute standard cycling exercise trials separated by approximately 3 to 7 days(osmolality and metabolites)
EXERCISE only: Fingertip capillary blood biomarkersTwo 90 minute standard cycling exercise trials separated by approximately 3 to 7 days(electrolytes and osmolality)
EXERCISE only: Biomechanical and physiological features associated with dehydration, fatigue, and energyTwo 90 minute standard cycling exercise trials separated by approximately 3 to 7 daysMeasured on staff iPad or iPhone to extract facial movements & voice quality features
Fitzpatrick scaleAt screeningClassification of skin type 1 through 6, 1=White skin. Always burns, never tans, to 6=Black skin. Heavily pigmented. Never burns, tans very easily.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026